NR5A1 and cytomegalovirus infection: Our previously published data show that ELP-P10 is a promising candidate for the development of an effective antiviral therapy against CMV infection; one potential limitation is its half-maximal inhibitory concentration (IC50) against MCMV, which was ~20-fold higher compared to unconjugated P10.